Current Atherosclerosis Reports

, Volume 9, Issue 2, pp 125–133

The role of CETP inhibition in dyslipidemia

  • Karim El Harchaoui
  • Wim A. van der Steeg
  • Erik S. G. Stroes
  • John J. P. Kastelein
Open AccessArticle

DOI: 10.1007/s11883-007-0008-5

Cite this article as:
El Harchaoui, K., van der Steeg, W.A., Stroes, E.S.G. et al. Curr Atheroscler Rep (2007) 9: 125. doi:10.1007/s11883-007-0008-5

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceriderich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.

Download to read the full article text

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Karim El Harchaoui
    • 1
  • Wim A. van der Steeg
  • Erik S. G. Stroes
  • John J. P. Kastelein
  1. 1.Department of Vascular Medicine, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands